We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05432583
Recruitment Status : Recruiting
First Posted : June 27, 2022
Last Update Posted : January 5, 2023
Sponsor:
Information provided by (Responsible Party):
BioNTech SE

Brief Summary:
This exploratory trial will have two parts. While Part A will focus on the safety evaluations, vaccine-induced immune responses (specifically neutralizing antibodies) will also be analyzed to assess if there is a dose-response. Part B of the trial will expand the safety characterization for a BNT163 dose selected based on Part A data and enable a more comprehensive assessment of the impact of pre-existing immunity to Herpes Simplex Virus (HSV)-1 and -2 on the safety and BNT163-induced immune responses after one selected (higher) dose of BNT163 than could be done during the dose escalation performed in Part A.

Condition or disease Intervention/treatment Phase
Genital Herpes Simplex Type 2 Biological: BNT163 Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: observer-blinded trial
Primary Purpose: Prevention
Official Title: Phase I, Randomized, Observer-blinded, Placebo-controlled, 2-part, Dose Escalation and Expanded Safety Evaluation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Prophylactic Vaccine for the Prevention of Genital Lesions Caused by Herpes Simplex Virus (HSV)-2 and Potentially HSV-1
Actual Study Start Date : December 8, 2022
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : June 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BNT163
Escalating dose levels
Biological: BNT163
Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection

Experimental: Placebo
Isotonic NaCl solution (0.9%)
Other: Placebo
Placebo




Primary Outcome Measures :
  1. Frequency of solicited local reactions at the injection site (pain, erythema/redness, induration/swelling) recorded up to 7 days after each investigational medicinal product (IMP) dose [ Time Frame: Up to 7 days after each dose ]
  2. Frequency of solicited systemic reactions (vomiting, diarrhea, headache, fatigue/tiredness, myalgia, arthralgia, chills, and fever) recorded up to 7 days after each IMP dose [ Time Frame: Up to 7 days after each dose ]
  3. Proportion of participants with at least one adverse event (AE) occurring up to 60 days post randomization in Part A [ Time Frame: From day 1 up to day 60 ]
  4. Proportion of participants with at least one AE occurring up to 60 days post randomization in Part B, then up to 28 days after Dose 3 in Part B [ Time Frame: From day 1 up to day 197 ]
  5. Proportion of participants in each cohort with at least one serious adverse event, or adverse event of special interest, or medically attended adverse event occurring up to 24 weeks post-Dose 3 [ Time Frame: From day 1 up to day 337 ]
  6. Number of unsolicited AEs from Dose 1 to 28 days post-Dose 3 [ Time Frame: From day 1 up to day 197 ]

Secondary Outcome Measures :
  1. Geometric mean titer (GMT) at each time point [ Time Frame: From day 1 up to day 337 ]
    HSV-2 glycoproteins (g)C2, gD2, and gE2 binding antibody titers enzyme-linked immunosorbent assay (ELISA). HSV-2 neutralizing antibody titers.

  2. Geometric mean fold (GMF) change from baseline of neutralizing and binding antibody titers to each time point after vaccination [ Time Frame: From day 1 up to day 337 ]
    HSV-2 gC2, gD2, and gE2 binding antibody titers (ELISA). HSV-2 neutralizing antibody titers.

  3. Proportion of participants with seroconversion defined as a minimum of 4-fold increase from baseline of neutralizing and binding antibody titers to each subsequent time point after vaccination [ Time Frame: From day 1 up to day 337 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 54 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Have given informed consent by signing and dating the informed consent form (ICF) before initiation of any trial-specific procedures.
  • Are aged 18 to less than 55 years, have a body mass index over 18.5 kg/m^2 and under 35 kg/m^2 and weigh at least 50 kg at Visit 0.
  • Are willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions (e.g., to practice social distancing and to follow good practices to reduce their chances of being infected or spreading COVID-19), and other requirements of the trial. This includes that they are able to understand and follow trial-related instructions.
  • Are overall healthy in the clinical judgment of the investigator based on medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and screening laboratory tests (blood clinical laboratory) at Visit 0.
  • Negative HIV-1 and HIV-2 blood test at Visit 0.
  • Negative Hepatitis B surface antigen at Visit 0.
  • Negative anti-Hepatitis C virus antibodies (anti-HCV), or undetectable hepatitis C virus (HCV) viral load if the anti-HCV is positive at Visit 0.
  • Negative syphilis test at Visit 0.
  • Volunteers of childbearing potential (VOCBP): negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test at Visit 0 and negative pregnancy test prior to each IMP administration and at the end of the trial. Volunteers born female that are postmenopausal or permanently sterilized will not be considered VOBCP.
  • VOCBP who agree to practice a highly effective form of contraception and to require their male partners to use condoms with a spermicidal agent, starting at Visit 0 and continuously until 60 days after receiving the last trial treatment.
  • VOCBP who agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting at Visit 0 and continuously until 60 days after receiving the last trial treatment.
  • Men who are sexually active with a VOCBP and have not had a vasectomy who agree to use condoms with a spermicidal agent and to practice a highly effective form of contraception with their partners of childbearing potential during the trial, starting at Visit 0 and continuously until 90 days after receiving the last trial treatment.
  • Men who are willing to refrain from sperm donation, starting at Visit 0 and continuously until 90 days after receiving the last trial treatment.
  • Have a negative drugs of abuse (for amphetamines, benzodiazepines, barbiturates, cocaine, cannabinoids, opiates, methadone, methamphetamines, phencyclidine, and tricyclic antidepressants) result at Visit 0 or Visit 1 at the discretion of the investigator.

Exclusion Criteria:

  • Breastfeeding or intending to become pregnant or father children within the projected duration of the trial starting with Visit 0 until 60 days after receiving the last trial treatment.
  • Current or history of genital herpes infections. Volunteers with oral herpes or herpetic whitlow will not be excluded.
  • Current or history of any form of ocular HSV infection or HSV-related central nervous system disease or complication.
  • History of any serious adverse reactions to vaccines or to vaccine components such as lipids, and including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded from participation: a volunteer who had an anaphylactic adverse reaction to pertussis vaccine as a child).
  • Current or history of the following medical conditions:

    • Uncontrolled or moderate or severe respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease); symptoms of asthma severity as defined in the most recent National Asthma Education and Prevention Program Expert Panel report;
    • History of thyroidectomy, or thyroid disease requiring medication during the last 12 months;
    • History of diabetes mellitus type 1 or type 2, including cases controlled with diet alone (Not excluded: history of isolated gestational diabetes);
    • Hypertension (elevated blood pressure or hypertension during screening or previously that is not well controlled only [consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤150 mm Hg systolic and ≤90 mm Hg diastolic at enrollment] or if systolic blood pressure ≥150 mm Hg at enrollment or diastolic blood pressure ≥100 mm Hg at enrollment);
    • Malignancy within 5 years of Visit 0, excluding localized basal or squamous cell cancer;
    • Any current or history of cardiovascular diseases, (e.g., myocarditis, pericarditis, myocardial infarction, congestive heart failure, cardiomyopathy or clinically significant arrhythmias), unless such disease is not considered relevant for participation in this trial in the investigator's judgment;
    • Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions);
    • Seizure disorder: History of seizure(s) within past 3 years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
  • History of psychiatric illness, including alcohol abuse or drug addiction within 1 year before Visit 0, or a history (within the past 5 years) of substance abuse or known medical, psychological, or social conditions which, in the opinion of the investigator, could compromise their wellbeing if they participate as participants in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Any of the following associated with immune dysregulation:

    • Primary immunodeficiencies.
    • History of solid organ or bone marrow transplantation.
    • Asplenia: any condition resulting in the absence of a functional spleen.
    • Currently existing or history of autoimmune disease, or family history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc.
  • Received any investigational research agents within 28 days before Visit 0.
  • Previous vaccination with an investigational herpes virus vaccine at any time.
  • Any non-trial vaccination within 28 days before any IMP dose in this trial unless medically indicated.
  • Received allergy treatment with antigen injections within 28 days before first IMP administration or that are scheduled within 14 days after Visit 1.
  • Received blood/plasma products or immunoglobulin within 120 days before Visit 1 or planned administration starting at Visit 0 until completion of Visit 12.
  • Received chronic suppressive antiviral therapy for treatment of recurrent HSV-1 and/or HSV-2 genital herpes infections (i.e., oral acyclovir, oral valacyclovir, oral famciclovir, and/or intravenous ganciclovir) from 1 year prior to Visit 0 until completion of Visit 12.
  • Any existing condition which may affect vaccine injection and/or assessment of local reactions assessment at the injection site, e.g., tattoos, severe scars, etc.
  • Vulnerable individuals as per International Council for Harmonisation (of Technical Requirements for Pharmaceuticals for Human Use) (ICH) E6 definition, i.e., are individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.
  • Any screening hematology and/or blood chemistry laboratory value that meets the definition of a Grade ≥1 abnormality at Visit 0.

Note: With the exception of bilirubin, participants with any stable Grade 1 abnormalities (according to the toxicity grading scale) may be considered eligible at the discretion of the investigator.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05432583


Contacts
Layout table for location contacts
Contact: BioNTech clinical trials patient information +49 6131 9084 ext 0 patients@biontech.de

Locations
Layout table for location information
United States, North Carolina
Accellacare Raleigh Medical Group Recruiting
Raleigh, North Carolina, United States, 27609
Accellacare PMG Research Wilmington LLC Recruiting
Wilmington, North Carolina, United States, 28401
Sponsors and Collaborators
BioNTech SE
Investigators
Layout table for investigator information
Study Director: BioNTech Responsible Person BioNTech SE
Layout table for additonal information
Responsible Party: BioNTech SE
ClinicalTrials.gov Identifier: NCT05432583    
Other Study ID Numbers: BNT163-01
First Posted: June 27, 2022    Key Record Dates
Last Update Posted: January 5, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BioNTech SE:
Prevention of genital lesions caused by herpes simplex virus-2
Prevention of genital lesions caused by herpes simplex virus-1
Genital infection caused by HSV
RNA Vaccine
Vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Herpes Simplex
Herpes Genitalis
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Infections
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Communicable Diseases